Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia
Open Access
- 4 February 2008
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 83 (6), 446-450
- https://doi.org/10.1002/ajh.21133
Abstract
We retrospectively analyzed 194 previously untreated acute myeloid leukemia (AML) patients to evaluate the role of Day 14 bone marrow (BM) biopsy in predicting complete remission (CR). Sixty‐seven percent received induction therapy. Achieving Day 14 BM ≤5% blasts was strongly predictive of Day 28 CR with 90% sensitivity and 79% positive predictive value; but weak 43% specificity and 29% negative predictive value. Day 14 BM biopsy is highly sensitive in predicting CR, but did not predict overall survival. Some patients with BM blast >5% at Day 14 may still achieve a Day 28 CR, and not necessarily need reinduction therapy though high risk cytochemical or cytogenetic phenotype predicts a need for retreatment. Am. J. Hematol., 2008.Keywords
This publication has 29 references indexed in Scilit:
- Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer CenterBlood, 2006
- New Strategies for the Treatment of Acute Myeloid Leukemia Including Antibodies and Other Novel AgentsHematology, 2005
- The benefit of induction chemotherapy in patients age ≥ 75 yearsCancer, 2004
- Acute Myeloid LeukemiaHematology, 2004
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Conservative treatment for patients over 80 years with acute myelogenous leukemiaAmerican Journal of Hematology, 2002
- Prognostic Factors in Elderly Patients with Acute Myelogenous Leukemia: A Single Center Study in JapanLeukemia & Lymphoma, 2002
- Age and Cytogenetics as Predictors of Event Free Survival in Patients with Acute Non-Lymphocytic Leukemia Receiving High Dose Cytosine Arabinoside and Daunorubicin as Consolidation ChemotherapyLeukemia & Lymphoma, 2001
- Anthracycline‐based therapy of de novo acute myeloid leukemia in adults: Failure of first‐cyde cytoreduction to predict second‐cycle outcomeAmerican Journal of Hematology, 1994
- Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup studyBritish Journal of Haematology, 1989